Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein

European Journal of Clinical Nutrition

Volumn 68, Issue 4, 2014, Pages 526-530

  Frankenfeld, C L ^a   Atkinson, C ^b   Wahala K ^c   Lampe, J W ^d  

^a GEORGE MASON UNIVERSITY   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; EQUOL; O DESMETHYANGOLENSIN; UNCLASSIFIED DRUG; ISOFLAVONE DERIVATIVE; O-DESMETHYLANGOLENSIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BACTERIAL METABOLISM; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME METABOLISM; ENZYME SYNTHESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOME; OBESITY; PHENOTYPE; PREVALENCE; URINALYSIS; VERY ELDERLY; ADOLESCENT; ANALYSIS; BIOSYNTHESIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; GASTROINTESTINAL TRACT; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; OVERWEIGHT; PHYSIOLOGY; SELF REPORT; SOYBEAN; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY WEIGHT; CROSS-SECTIONAL STUDIES; EQUOL; FEMALE; GASTROINTESTINAL TRACT; HUMANS; ISOFLAVONES; MALE; MICROBIOTA; MIDDLE AGED; OBESITY; OVERWEIGHT; PHENOTYPE; PREVALENCE; SELF REPORT; SOY FOODS; YOUNG ADULT;

EID: 84898009943     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2014.23     Document Type: Article

References (43)

1. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-435.
2. Hullar MA, Lampe JW. The gut microbiome and obesity. Nestle Nutr Workshop Ser 2012; 73: 67-79.
3. Nakamura Y, Tsuji S, Tonogai Y. Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int 2000; 83: 635-650.
4. Setchell KD, Clerici C. Equol: Pharmacokinetics and biological actions. J Nutr 2010; 140: 1363S-1368S
5. Frankenfeld CL O-desmethylangolensin: The importance of equol's lesser known cousin to human health. Adv Nutr 2011; 2: 317-324.
6. Heinonen S, Wähälä K, Adlercreutz H. Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6'-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem 1999; 274: 211-219.
7. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med (Maywood) 2005; 230: 155-170.
8. Setchell KD, Clerici C. Equol: History, chemistry, and formation. J Nutr 2010; 140: 1355S-1362S.
9. Frankenfeld CL, Atkinson C, Thomas WK, Gonzalez A, Jokela T, Wähälä K et al. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 2005; 94: 873-876.
10. Song KB, Atkinson C, Frankenfeld CL, Jokela T, Wähälä K, Thomas WK et al. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr 2006; 136: 1347-1351.
11. Lampe JW. Is equol the key to the efficacy of soy foods? Am J Clin Nutr 2009; 89: 1664S-1667S
12. Shor D, Sathyapalan T, Atkin S, Thatcher N. Does equol production determine soy endocrine effects? Eur J Nutr 2012; 51: 389-398.
13. Frankenfeld CL. Relationship of obesity and high urinary enterolignan concentrations in 6806 children and adults: Analysis of National Health and Nutrition Examination Survey data. Eur J Clin Nutr 2013; 67: 887-889.
14. Frankenfeld CL, Atkinson C, Thomas WK, Goode EL, Gonzalez A, Jokela T et al. Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med (Maywood) 2004; 229: 902-913.
15. Frankenfeld CL, McTiernan A, Tworoger SS, Atkinson C, Thomas WK, Stanczyk FZ et al. Serum steroid hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated estrogen metabolites in post-menopausal women in relation to daidzein-metabolizing phenotypes. J Steroid Biochem Mol Biol 2004; 88: 399-408.
16. World Health Organization (WHO) Obesity and overweight. Fact Sheet No. 311. 2012.
17. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26: 5-11.
18. Finegold SM, Attebery HR, Sutter VL. Effect of diet on human fecal flora: Comparison of Japanese and American diets. Am J Clin Nutr 1974; 27: 1456-1469.
19. Benno Y, Endo K, Mizutani T, Namba Y, Komori T, Mitsuoka T. Comparison of fecal microflora of elderly persons in rural and urban areas of Japan. Appl Environ Microbiol 1989; 55: 1100-1105.
20. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: A cross-sectional study. Appl Environ Microbiol 2006; 72: 1027-1033.
21. Zhao L, Xu W, Ibrahim SA, Jin J, Feng J, Jiang J et al. Effects of age and region on fecal microflora in elderly subjects living in Bama, Guangxi, China. Curr Microbiol 2011; 62: 64-70.
22. Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaCroix K, Schramm J et al. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1156-1162.
23. Frankenfeld CL, McTiernan A, Thomas WK, LaCroix K, McVarish L, Holt VL et al. Postmenopausal bone mineral densityin relation to soy isoflavone- metabolizing phenotypes. Maturitas 2006; 53: 315-324.
24. Atkinson C, Newton KM, Aiello Bowles EJ, Lehman CD, Stanczyk FZ, Westerlind KC et al. Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res Treat 2009; 116: 587-594.
25. Atkinson C, Newton KM, Stanczyk FZ, Westerlind KC, Li L, Lampe JW. Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States. Cancer Causes Control 2008; 19: 1085-1093.
26. Atkinson C, Newton KM, Yong M, Stanczyk FZ, Westerlind KC, Li L et al. Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States. Metabolism 2012; 61: 1678-1682.
27. Bolca S, Van De Wiele T, Possemiers S. Gut metabotypes govern health effects of dietary polyphenols. Curr Opin Biotechnol 2012; 24: 220-225.
28. Schoefer L, Mohan R, Braune A, Birringer M, Blaut M. Anaerobic C-ring cleavage of genistein and daidzein by Eubacterium ramulus. FEMS Microbiol Lett 2002; 208: 197-202.
29. Hur HG, Beger RD, Heinze TM, Lay JO Jr, Freeman JP, Dore J et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. Arch Microbiol 2002; 178: 8-12.
30. Schneider H, Blaut M. Anaerobic degradation of flavonoids by Eubacterium ramulus. Arch Microbiol 2000; 173: 71-75.
31. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484.
32. Gil-Izquierdo A, Penalvo JL, Gil JI, Medina S, Horcajada MN, Lafay S et al. Soy isoflavones and cardiovascular disease epidemiological, clinical and -omics perspectives. Curr Pharm Biotechnol 2012; 13: 624-631.
33. Ishimi Y. Soybean isoflavones in bone health. Forum Nutr 2009; 61: 104-116.
34. Jackman KA, Woodman OL, Sobey CG. Isoflavones equol and cardiovascular disease: Pharmacological and therapeutic insights. Curr Med Chem 2007; 14: 2824-2830.
35. Jackson RL, Greiwe JS, Schwen RJ. Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 2011; 69: 432-448.
36. Martin D, Song J, Mark C, Eyster K. Understanding the cardiovascular actions of soy isoflavones: Potential novel targets for antihypertensive drug development. Cardiovasc Hematol Disorders Drug Targets 2008; 8: 297-312.
37. Wiseman H. The therapeutic potential of phytoestrogens. Exp Opin Invest Drugs 2000; 9: 1829-1840.
38. Yuan JP, Wang JH, Liu X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora-implications for health. Mol Nutr Food Res 2007; 51: 765-781.
39. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-A clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132: 3577-3584.
40. Lampe JW. Emerging research on equol and cancer. J Nutr 2010; 140: 1369S-1372S
41. Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull 2009; 32: 195-202.
42. Pfitscher A, Reiter E, Jungbauer A. Receptor binding and transactivation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol 2008; 112: 87-94.
43. Lourdes M, Cruz A, Wong WW, Mimouni F, Hachey DL, Setchell KDR et al. Effects of infant nutrition on cholesterol synthesis rates. Pediatr Res 1994; 35: 135-140.